NaviGate Cardiac Structures, Inc., presents data of studies on the Gate™ valved stent for correction of Functional Tricuspid Regurgitation at Paris PCR2016.


Jun 23, 2016   •  Announcement

Jose L Navia, M.D., from Cleveland Clinic presented the summary of animal studies of the Gate™valved stent for catheter-guided orthotopic implantation procedure for the correction of Functional Tricuspid Regurgitation (FTR).  Functional tricuspid regurgitation occurs yearly in close to 2 million patients in the USA, as reported by Stuge & Liddicoat previously.  These patients are for a large part categorized as inoperable by the STS (Society of Thoracic Surgery) guidelines, that is, at…

Continue Reading

First NAVI™ patient at 8 months shows excellent mitral valve function and has returned to work


Jun 23, 2016   •  Announcement

NaviGate Cardiac Structures, Inc. has received approval from Krakow, Poland, Ethics Committee  to implant the Navi™ Valved Stent for correction of severe Functional Mitral Regurgitation (FMR). NCSI has received approval from the regional Ethics Committee to implant the Navi™valved stent for the correction of severe mitral regurgitation (MR) in patients considered inoperable by standard cardiac surgery that requires open chest, open and arrested heart and cardiopulmonary bypass because of…

Continue Reading